Rapid Antigen Testing Market Size

Rapid Antigen Testing Market size was over USD 25.68 billion in 2024 and is projected to reach USD 64.96 billion by 2037, growing at around 7.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of rapid antigen testing is assessed at USD 27.2 billion. Rapid antigen testing is in high demand as a result of the COVID-19 pandemic because people, companies, and governments want to find speedy ways to detect infected people and stop the virus from spreading.

 Also, the accuracy provided by these tests during the COVID-19 increased their demand during the pandemic. According to a study in 2022, antigen testing accurately detected COVID-19 infection in 73% of symptomatic individuals with confirmed COVID-19, compared to 55% of asymptomatic individuals.  Rapid antigen testing is a crucial weapon in the pandemic response since it can yield results in as little as 15 minutes.

Several regulatory bodies, including the US FDA, the European Union, and other national regulatory bodies, have approved rapid antigen testing for use which will drive the rapid antigen testing market demand to increase rapidly. Rapid antigen testing is now more widely available and used as a result of this. For instance, the Flowflex COVID-19 Antigen Home Test, the first and second COVID-19 at-home tests to satisfactorily pass traditional premarket evaluation, was approved for commercialization by the Food and Drug Administration on November 9.